PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
June 19, 2024Blood Cancer Discovery

Abstract PR06: Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXubin LiKSKartik SinghalQDQing Deng

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e64292b6db6435875d3e61https://doi.org/10.1158/2643-3249.lymphoma24-pr06
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy2024
  2. 2Abstract LB346: Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene ciloleucel (axi-cel) treatment2024 · 1 citations
  3. 3Abstract 7944: Tumor immune micro-environment (TME) dynamics in longitudinal diffuse large B-cell lymphoma (DLBCL) cases from diagnosis to RCHOP relapse2026
  4. 4Abstract IA005: Analysis of site-specific CAR T cell efficacy in LBCL and development of novel engineering strategies2026
  5. 5Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025